IL1B and Hepatic fibrosis: As it is shown in Fig. 3, The 7.5 mg/kg dose of NIC reduced IL-6 and IL-1β levels by 40.77% and 35.29%, respectively, while increasing IL-10 levels by 163.64%, relative to the TAA-induced liver fibrosis group.